Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of early pregnancy location and viability compared with hCG, progesterone and estradiol

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Glycodelin is internalized by peripheral monocytes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Plasma YKL-40 during pregnancy and gestational diabetes mellitus

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Phenotypic characterisation of immune cell infiltrates in testicular germ cell neoplasia

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The presence of HLA-antibodies in recurrent miscarriage patients is associated with a reduced chance of a live birth

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

A circulating biomarker of early pregnancy outcome independent of ultrasonography and gestational age is a coveted goal. This study evaluated soluble urokinase plasminogen activator receptor (suPAR), a well-described marker of inflammation and immunological activation, for this purpose, and compared it with established early pregnancy biomarkers of the luteoplacental phase: progesterone, estradiol and hCG. We merged data from two prospective first trimester cohorts to conduct a case-control study comparing these analytes in women who had either a live birth, a miscarriage or an ectopic pregnancy. The ability to predict pregnancy location and viability was assessed by areas under the receiver operating characteristic curves (AUC). Comparing women irrespective of gestational age with a live birth, miscarriage or ectopic pregnancy showed significantly lower suPAR values in the latter group (2.4 vs. 2.4 vs. 2.0 μg/L, p = 0.032, respectively), as were all other analytes. Before 6 weeks' gestation, suPAR was significantly inferior to progesterone, estradiol and hCG in pregnancy location and viability prediction (in 124 pregnancies, suPAR AUClocation = 0.69 [CI: 0.54-0.83] and AUCviability = 0.58 [CI: 0.48-0.69], while progesterone AUClocation = 0.95 [CI: 0.87-1.00] and AUCviability = 0.84 [CI: 0.75-0.92]). After 6 weeks' gestation, suPAR prediction improved but was inferior to hCG, progesterone and estradiol (in 188 pregnanices, suPAR AUClocation = 0.71 [CI: 0.63-0.78] and AUCviability = 0.70 [CI: 0.63-0.78] compared with hCG AUClocation = 0.96 [CI: 0.93-0.99] and AUCviability = 0.96 [CI: 0.93-0.98]). Collectively, suPAR is less useful as a predictor of early pregnancy outcome than hCG, progesterone and estradol.

Original languageEnglish
JournalJournal of Reproductive Immunology
Pages (from-to)103103
Publication statusPublished - Apr 2020

    Research areas

  • Early pregnancy, Ectopic pregnancy, Live birth, Progesterone, suPAR

ID: 59518054